HILLEVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.79 USD | +6.41% |
|
+3.98% | -20.31% |
| Apr. 05 | Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing | MT |
| Mar. 21 | Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating | MT |
Chart calendar HilleVax, Inc.
dade640d6de5.q616NkIndSow-zpBgmVaQ2aZp5e8mQkWFkLrI_97eIc.2fszcHYQEHxkznVw6TVtGzzD7_bkwWRwchrdcMoeAOba3AsECEpFcmC-cw~7550fc8a71f85cb98dd7c98d12dd1170
Upcoming events on HilleVax, Inc.
Past events on HilleVax, Inc.
| 2024-03-20 04:00 pm | Q4 2023 Earnings Release |
| 2024-02-07 02:00 pm | Guggenheim Healthcare Talks Biotechnology Conference |
| 2024-01-08 04:30 pm | JPMorgan Healthcare Conference |
| 2023-11-14 11:30 am | Stifel Healthcare Conference |
| 2023-11-09 04:05 pm | Q3 2023 Earnings Release |
| 2023-11-06 03:10 pm | Guggenheim Securities Inflammation & Immunology Conference |
| 2023-09-28 12:40 pm | Cantor Global Healthcare Conference |
| 2023-08-14 07:00 am | Q2 2023 Earnings Release |
| 2023-06-07 11:30 am | Annual General Meeting |
| 2023-03-17 04:05 pm | Q4 2022 Earnings Release |
| 2023-01-09 04:30 pm | JP Morgan Healthcare Conference |
| 2022-11-16 08:35 am | Stifel Healthcare Conference |
| 2022-11-14 03:55 pm | Guggenheim Securities Immunology and Neurology Day |
| 2022-11-10 04:05 pm | Q3 2022 Earnings Release |
| 2022-09-06 01:00 pm | J.P Morgan Biotech Conference |
| 2022-08-18 03:00 pm | SVB Securities Virtual Vaccine Forum - Fireside Chat |
| 2022-08-10 04:01 pm | Interim 2022 Earnings Release |
| 2022-06-07 | Q1 2022 Earnings Release |
Annual results
| Fiscal Period | December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -65,1 -115 43.38% | -133 -131 -1.31% | -162 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -65,1 -96,5 32.52% | -133 -134 0.81% | -166 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -160 -193 16.98% | -124 -126 2.06% | -158 |
|
Net income Million USD | Released Forecast Spread | -102 | -160 -188 15% | -124 -126 2.22% | -160 |
|
EPS USD | Released Forecast Spread | -30,6 | -5,89 -7,20 18.18% | -3,04 -3,08 1.19% | -3,10 |
| Announcement Date | 28/02/22 | 17/03/23 | 20/03/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -11,3 -17,0 33.45% | -12,8 -21,0 39.01% | -17,9 -33,0 45.78% | -23,1 -73,0 68.36% | -29,0 -28,0 -3.43% | -30,1 -34,0 11.53% | -33,6 -35,0 4.09% | -39,4 -38,0 -3.72% | |||||
|
EBIT Million USD | Released Forecast Spread | -11,3 -12,6 10.15% | -12,8 -17,9 28.38% | -17,9 -28,1 36.38% | -23,1 -54,5 57.6% | -29,0 -7,28 -297.95% | -30,2 -35,8 15.75% | -33,9 -34,1 0.7% | -40,3 -41,4 2.58% | -42,6 | -45,3 | -39,7 | -33,8 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -67,9 -16,6 -309.67% | -53,9 -21,5 -151.28% | -16,8 -28,3 40.66% | -21,2 -53,8 60.59% | -26,9 -37,1 27.62% | -27,9 -34,6 19.33% | -31,8 -32,0 0.68% | -37,0 -39,5 6.53% | -40,6 | -43,2 | -39,5 | -35,3 | |
|
Net income Million USD | Released Forecast Spread | -67,9 -16,6 -309.67% | -53,9 -24,0 -124.94% | -16,8 -28,2 40.49% | -21,2 -49,6 57.26% | -26,9 -35,5 24.23% | -27,9 -34,2 18.45% | -31,8 -31,8 -0.04% | -37,0 -39,8 7.12% | -40,6 | -43,2 | -39,5 | -35,3 | |
|
EPS USD | Released Forecast Spread | -10,1 -2,87 -250.78% | -2,03 -0,87 -132.97% | -0,45 -0,91 50.56% | -0,56 -1,46 61.64% | -0,71 -0,94 24.81% | -0,74 -0,91 18.25% | -0,81 -0,84 3.5% | -0,78 -0,83 6.22% | -0,85 | -0,90 | -0,74 | -0,67 | |
| Announcement Date | 08/06/22 | 10/08/22 | 10/11/22 | 17/03/23 | 12/05/23 | 14/08/23 | 09/11/23 | 20/03/24 | - | - | - | - | - |
| Today 04:05 pm | QIAGEN N.V.: Q1 2024 Earnings Release |
| 2024-04-29 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-05-01 06:30 am | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 2024-05-01 06:30 am | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 2024-05-01 07:00 am | ALKERMES PLC: Q1 2024 Earnings Release |
| 2024-05-01 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for HilleVax, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- HLVX Stock
- Calendar HilleVax, Inc.
